Valuation: XTL Biopharmaceuticals Ltd.

Market Cap 5.9M 0 5.28M 4.86M 4.4M 8.23M 560M 8.38M 57.95M 23.26M 295M 22.14M 21.67M 929M P/E 2024
-7.08x
P/E 2025 -0.96x
Enterprise Value 5.82M 0 5.22M 4.8M 4.35M 8.12M 553M 8.28M 57.2M 22.96M 291M 21.85M 21.39M 917M EV / Sales 2024
47,405,414x
EV / Sales 2025 -
Free-Float
75.44%
Yield 2024 *
-
Yield 2025 -
1 week-6.67%
1 month-22.22%
3 months-30.00%
6 months-41.67%
Current year-41.67%
1 week 1.4
Extreme 1.4
1.5
1 month 1.4
Extreme 1.4
1.9
Current year 1.4
Extreme 1.4
4.4
1 year 1.4
Extreme 1.4
4.4
3 years 1.4
Extreme 1.4
17.1
5 years 1.4
Extreme 1.4
17.1
10 years 1.4
Extreme 1.4
19.2
Manager TitleAgeSince
Chief Executive Officer 56 07/04/2025
Director of Finance/CFO - 30/11/2025
Director TitleAgeSince
Chairman 64 07/04/2025
Director/Board Member 60 01/03/2015
Director/Board Member 59 29/01/2020
Date Insider Type Main position Quantity % Market Cap. Importance
3/18/26 A Other

Director

1,000,000 0.1057%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-6.67%-63.16%-56.25% 5.9M
-0.62%-1.87%+42.87%+64.15% 63.77B
+0.35%+3.20%+14.40%+81.76% 56.37B
+0.53%+1.96%+16.24%+103.35% 54.62B
-2.81%-4.31%+23.50%+47.83% 44.06B
-0.33%-1.93%+19.28%+98.80% 42.11B
+0.55%+2.31%+225.14%+866.21% 41B
+3.27%+47.96%+112.84%+96.58% 34.92B
+1.22%-1.44%+14.57%+46.95% 32.82B
+0.89%+20.55%-40.62%+349.24% 24.7B
Average +0.31%+6.12%+36.50%+169.86% 39.43B
Weighted average by Cap. +0.18%+5.44%+47.99%+176.67%

Financials

2024 2025
Net sales 0.45 0 0.4 0.37 0.34 0.63 42.82 0.64 4.43 1.78 22.53 1.69 1.66 71.04 -
Net income -1.03M -0 -920K -846K -767K -1.43M -97.51M -1.46M -10.09M -4.05M -51.3M -3.85M -3.77M -162M -6.97M -0 -6.24M -5.74M -5.2M -9.72M -662M -9.91M -68.46M -27.48M -348M -26.15M -25.6M -1.1B
Net Debt -1M -0 -900K -828K -750K -1.4M -95.43M -1.43M -9.87M -3.96M -50.2M -3.77M -3.69M -158M -76K -0 -68.07K -62.61K -56.73K -106K -7.22M -108K -747K -300K -3.8M -285K -279K -11.97M
Projected Income Statement - Annual - XTL Biopharmaceuticals Ltd.
Logo XTL Biopharmaceuticals Ltd.
X T L Biopharmaceuticals Ltd (Xenograft Technologies Ltd) is an Israel-based biopharmaceutical company engaged in acquisition and development of pharmaceutical drugs for treatment of autoimmune diseases. The Company pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong a survival of patients for treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by kidneys. EPO stimulates erythropoiesis, production of red blood cells, by binding to its receptor on a surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.
Employees
5
Date Price Change Volume
30/10/26 ILA 1.400 -.--% 778,000
29/10/26 ILA 1.400 -.--% 458,200
28/10/26 ILA 1.400 -6.67% 1,796,138
26/10/26 ILA 1.500 -.--% 21,000
23/10/26 ILA 1.500 -.--% 377,202
  1. Stock Market
  2. Stocks
  3. XTLB Stock